NextCure, Inc.
NextCure, Inc. (NXTC) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · NXTC · as of Sep 30, 2025
Ownership Breakdown
17
Institutional Holders
▼ 13 vs Q2
$5.03M
Total Inst. Value
▼ $621,628 vs Q2
2.68M
Shares Outstanding
freeFloat 59.56%
858,076
13F Shares Held
▼ 9.69M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
NXTC largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
SOFINNOVA INVESTMENTS, INC. pharmaceutical preparations | 222.7K | 8.32% | 8.32% | $1.30B | Nov 14, 2025 | NEW |
AFFINITY ASSET ADVISORS, LLC pharmaceutical preparations | 191.9K | 7.17% | 7.17% | $1.12B | Nov 13, 2025 | NEW |
PFIZER INC pharmaceutical preparations | 157.6K | 5.89% | 5.89% | $923.81M | Nov 13, 2025 | NEW |
VANGUARD GROUP INC pharmaceutical preparations | 68.0K | 2.54% | 2.54% | $398.38M | Nov 7, 2025 | NEW |
BARCLAYS PLC pharmaceutical preparations | 67.5K | 2.52% | 2.52% | $92.50M | Mar 19, 2026 | — held |
CABLE CAR CAPITAL LLC pharmaceutical preparations | 63.2K | 2.36% | 2.36% | $370.22M | Nov 14, 2025 | NEW |
ACADIAN ASSET MANAGEMENT LLC pharmaceutical preparations | 36.7K | 1.37% | 1.37% | $213.00M | Nov 13, 2025 | NEW |
BLACKROCK, INC. pharmaceutical preparations | 31.1K | 1.16% | 1.16% | $182.16M | Nov 12, 2025 | NEW |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 28.3K | 1.06% | 1.06% | $166.04M | Nov 13, 2025 | NEW |
CARDIFF PARK ADVISORS, LLC pharmaceutical preparations | 21.8K | 81.58% | 81.58% | $127.94M | Nov 14, 2025 | ▼ 240.2K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
0
Increased
+0 shares16
New Positions
first time holders1
Decreased
−240.2K shares28
Sold Out
fully exitedNet shares change (top 50)
240.2K
+0 / −240.2K
Net new holders
-13
16 new / 28 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
NXTC insider trading · insider activity
Source: SEC Form 4
6
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Shaw Kevin G. Sr VP, General Counsel | Jan 30, 2026 | Award | 8,270 | $10.85 | $89.7K | 8.3K | Form 4 ↗ |
Guha Udayan Chief Medical Officer | Jan 30, 2026 | Award | 14,670 | $10.85 | $159.2K | 14.7K | Form 4 ↗ |
Kundu Sourav Sr VP, Dev. & Mfg. | Jan 30, 2026 | Award | 8,270 | $10.85 | $89.7K | 8.3K | Form 4 ↗ |
Mayer Timothy Chief Operating Officer | Jan 30, 2026 | Award | 14,670 | $10.85 | $159.2K | 14.7K | Form 4 ↗ |
Richman Michael President & CEO | Jan 30, 2026 | Award | 38,190 | $10.85 | $414.4K | 38.2K | Form 4 ↗ |
Cobourn Steven P. Chief Financial Officer | Jan 30, 2026 | Award | 14,670 | $10.85 | $159.2K | 14.7K | Form 4 ↗ |
Houston John G director | Jun 20, 2025 | Award | 18,700 | $0.47 | $8.8K | 18.7K | Form 4 ↗ |
Jones Elaine V director | Jun 20, 2025 | Award | 18,700 | $0.47 | $8.8K | 18.7K | Form 4 ↗ |
KABAKOFF DAVID S director | Jun 20, 2025 | Award | 28,050 | $0.47 | $13.2K | 28.1K | Form 4 ↗ |
Borgman Anne Elizabeth director | Jun 20, 2025 | Award | 18,700 | $0.47 | $8.8K | 18.7K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
NextCure, Inc. (NXTC) is primarily owned by institutional investors, who hold approximately 32.0% of total shares outstanding. Company insiders own approximately 40.44%, while retail and public investors account for the remaining 27.54%.
The largest institutional shareholder of NextCure, Inc. is SOFINNOVA INVESTMENTS, INC., holding approximately 222,654 shares — equal to 8.32% of outstanding shares — as of September 30, 2025.
A total of 17 institutional investors currently hold NXTC stock, with a combined institutional value of approximately $5,026,436 as of the most recent 13F filing period.
Frequently asked questions
NXTC ownershipNextCure, Inc. (NXTC) is primarily owned by institutional investors, who hold approximately 32.0% of shares. The largest shareholder is SOFINNOVA INVESTMENTS, INC. with a 8.32% stake. Company insiders hold 40.44%. Data sourced from SEC Form 13F as of September 30, 2025.